Daiwa Securities Group Inc. decreased its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 10.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,265 shares of the medical equipment provider’s stock after selling 717 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Zimmer Biomet were worth $756,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Longview Partners Guernsey LTD lifted its stake in Zimmer Biomet by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after buying an additional 1,128,973 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in Zimmer Biomet by 249.3% in the third quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after buying an additional 727,925 shares in the last quarter. Jana Partners LLC lifted its stake in Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after buying an additional 662,497 shares in the last quarter. American Century Companies Inc. lifted its stake in Zimmer Biomet by 14.7% in the fourth quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock valued at $576,488,000 after buying an additional 612,044 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Zimmer Biomet by 24.4% in the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock valued at $323,134,000 after buying an additional 541,102 shares in the last quarter. 86.36% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on ZBH shares. SunTrust Banks set a $136.00 price target on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies lowered shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 2nd. BMO Capital Markets cut their price target on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. Morgan Stanley cut their price target on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet has an average rating of “Buy” and an average target price of $141.67.
In related news, VP Chad F. Phipps sold 20,826 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.07% of the stock is currently owned by insiders.
Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at $120.48 on Friday. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76. The company has a market cap of $24,254.25, a price-to-earnings ratio of 13.37, a PEG ratio of 2.10 and a beta of 1.08. Zimmer Biomet Holdings Inc has a 1 year low of $108.03 and a 1 year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting the Zacks’ consensus estimate of $2.10. The business had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.14 earnings per share. research analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. Zimmer Biomet’s payout ratio is 10.65%.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2018/02/18/zimmer-biomet-holdings-inc-zbh-position-trimmed-by-daiwa-securities-group-inc.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.